vs
BICYCLE THERAPEUTICS PLC（BCYC）与RE/MAX Holdings, Inc.（RMAX）财务数据对比。点击上方公司名可切换其他公司
RE/MAX Holdings, Inc.的季度营收约是BICYCLE THERAPEUTICS PLC的1.5倍（$71.1M vs $48.0M），RE/MAX Holdings, Inc.净利率更高（2.0% vs -42.0%，领先44.1%），BICYCLE THERAPEUTICS PLC同比增速更快（1193.3% vs -1.8%），RE/MAX Holdings, Inc.自由现金流更多（$33.5M vs $-19.9M），过去两年BICYCLE THERAPEUTICS PLC的营收复合增速更高（56.7% vs -4.7%）
Bicycle Therapeutics是一家临床阶段生物制药企业，专注于开发双环肽类创新疗法以解决未被满足的医疗需求，核心管线覆盖肿瘤、罕见病与免疫疾病领域，在欧美布局运营，与全球头部药企达成战略合作推进候选药物落地。
RE/MAX是全球知名的房地产特许经营机构，业务遍布全球一百多个国家和地区，旗下拥有数千家门店，总计超过十万名房产经纪人，在国际房产中介领域拥有极高的品牌知名度与市场影响力。
BCYC vs RMAX — 直观对比
营收规模更大
RMAX
是对方的1.5倍
$48.0M
营收增速更快
BCYC
高出1195.1%
-1.8%
净利率更高
RMAX
高出44.1%
-42.0%
自由现金流更多
RMAX
多$53.4M
$-19.9M
两年增速更快
BCYC
近两年复合增速
-4.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $48.0M | $71.1M |
| 净利润 | $-20.2M | $1.4M |
| 毛利率 | — | — |
| 营业利润率 | -51.5% | 13.1% |
| 净利率 | -42.0% | 2.0% |
| 营收同比 | 1193.3% | -1.8% |
| 净利润同比 | 61.1% | -75.2% |
| 每股收益（稀释后） | $-0.29 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BCYCRMAX
| Q4 25 | $48.0M | $71.1M | ||
| Q3 25 | $11.7M | $73.2M | ||
| Q2 25 | $2.9M | $72.8M | ||
| Q1 25 | $10.0M | $74.5M | ||
| Q4 24 | $3.7M | $72.5M | ||
| Q3 24 | $2.7M | $78.5M | ||
| Q2 24 | $9.4M | $78.5M | ||
| Q1 24 | $19.5M | $78.3M |
净利润BCYCRMAX
| Q4 25 | $-20.2M | $1.4M | ||
| Q3 25 | $-59.1M | $4.0M | ||
| Q2 25 | $-79.0M | $4.7M | ||
| Q1 25 | $-60.8M | $-2.0M | ||
| Q4 24 | — | $5.8M | ||
| Q3 24 | $-50.8M | $966.0K | ||
| Q2 24 | $-39.8M | $3.7M | ||
| Q1 24 | $-26.6M | $-3.4M |
营业利润率BCYCRMAX
| Q4 25 | -51.5% | 13.1% | ||
| Q3 25 | -558.6% | 25.0% | ||
| Q2 25 | -2965.8% | 19.3% | ||
| Q1 25 | -703.7% | 7.2% | ||
| Q4 24 | — | 5.9% | ||
| Q3 24 | -2385.9% | 19.4% | ||
| Q2 24 | -498.3% | 20.6% | ||
| Q1 24 | -162.4% | 5.8% |
净利率BCYCRMAX
| Q4 25 | -42.0% | 2.0% | ||
| Q3 25 | -503.7% | 5.4% | ||
| Q2 25 | -2703.8% | 6.4% | ||
| Q1 25 | -608.9% | -2.6% | ||
| Q4 24 | — | 8.0% | ||
| Q3 24 | -1898.4% | 1.2% | ||
| Q2 24 | -425.3% | 4.7% | ||
| Q1 24 | -136.0% | -4.3% |
每股收益（稀释后）BCYCRMAX
| Q4 25 | $-0.29 | — | ||
| Q3 25 | $-0.85 | — | ||
| Q2 25 | $-1.14 | — | ||
| Q1 25 | $-0.88 | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.74 | — | ||
| Q2 24 | $-0.77 | — | ||
| Q1 24 | $-0.62 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $628.1M | $118.7M |
| 总债务越低越好 | — | $432.2M |
| 股东权益账面价值 | $610.0M | $452.4M |
| 总资产 | $717.6M | $582.5M |
| 负债/权益比越低杠杆越低 | — | 0.96× |
8季度趋势，按日历期对齐
现金及短期投资BCYCRMAX
| Q4 25 | $628.1M | $118.7M | ||
| Q3 25 | $648.3M | $107.5M | ||
| Q2 25 | $721.5M | $94.3M | ||
| Q1 25 | $793.0M | $89.1M | ||
| Q4 24 | $879.5M | $96.6M | ||
| Q3 24 | $890.9M | $83.8M | ||
| Q2 24 | $961.4M | $66.1M | ||
| Q1 24 | $457.0M | $82.1M |
总债务BCYCRMAX
| Q4 25 | — | $432.2M | ||
| Q3 25 | — | $433.3M | ||
| Q2 25 | — | $434.4M | ||
| Q1 25 | — | $435.3M | ||
| Q4 24 | — | $436.2M | ||
| Q3 24 | — | $437.2M | ||
| Q2 24 | $30.9M | $438.1M | ||
| Q1 24 | $30.8M | $439.0M |
股东权益BCYCRMAX
| Q4 25 | $610.0M | $452.4M | ||
| Q3 25 | $618.5M | $448.1M | ||
| Q2 25 | $668.9M | $442.4M | ||
| Q1 25 | $740.3M | $433.5M | ||
| Q4 24 | $793.1M | $429.5M | ||
| Q3 24 | $831.0M | $423.1M | ||
| Q2 24 | $873.8M | $418.4M | ||
| Q1 24 | $356.0M | $412.0M |
总资产BCYCRMAX
| Q4 25 | $717.6M | $582.5M | ||
| Q3 25 | $764.0M | $582.2M | ||
| Q2 25 | $832.2M | $574.8M | ||
| Q1 25 | $883.9M | $571.4M | ||
| Q4 24 | $956.9M | $581.6M | ||
| Q3 24 | $996.7M | $578.6M | ||
| Q2 24 | $1.1B | $571.4M | ||
| Q1 24 | $547.1M | $566.7M |
负债/权益比BCYCRMAX
| Q4 25 | — | 0.96× | ||
| Q3 25 | — | 0.97× | ||
| Q2 25 | — | 0.98× | ||
| Q1 25 | — | 1.00× | ||
| Q4 24 | — | 1.02× | ||
| Q3 24 | — | 1.03× | ||
| Q2 24 | 0.04× | 1.05× | ||
| Q1 24 | 0.09× | 1.07× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-19.3M | $40.9M |
| 自由现金流经营现金流 - 资本支出 | $-19.9M | $33.5M |
| 自由现金流率自由现金流/营收 | -41.5% | 47.1% |
| 资本支出强度资本支出/营收 | 1.2% | 10.4% |
| 现金转化率经营现金流/净利润 | — | 28.39× |
| 过去12个月自由现金流最近4个季度 | $-252.0M | $56.8M |
8季度趋势，按日历期对齐
经营现金流BCYCRMAX
| Q4 25 | $-19.3M | $40.9M | ||
| Q3 25 | $-71.2M | $17.7M | ||
| Q2 25 | $-72.8M | $4.6M | ||
| Q1 25 | $-86.4M | $5.7M | ||
| Q4 24 | $-164.7M | $59.7M | ||
| Q3 24 | $-39.8M | $17.6M | ||
| Q2 24 | $-44.6M | $15.9M | ||
| Q1 24 | $-70.9M | $9.4M |
自由现金流BCYCRMAX
| Q4 25 | $-19.9M | $33.5M | ||
| Q3 25 | $-71.8M | $16.4M | ||
| Q2 25 | $-73.3M | $2.9M | ||
| Q1 25 | $-87.0M | $4.0M | ||
| Q4 24 | $-166.0M | $53.0M | ||
| Q3 24 | $-40.3M | $16.3M | ||
| Q2 24 | $-45.0M | $14.0M | ||
| Q1 24 | $-70.9M | $6.8M |
自由现金流率BCYCRMAX
| Q4 25 | -41.5% | 47.1% | ||
| Q3 25 | -612.3% | 22.4% | ||
| Q2 25 | -2509.7% | 4.0% | ||
| Q1 25 | -871.7% | 5.3% | ||
| Q4 24 | -4475.7% | 73.2% | ||
| Q3 24 | -1504.7% | 20.8% | ||
| Q2 24 | -481.2% | 17.8% | ||
| Q1 24 | -362.9% | 8.6% |
资本支出强度BCYCRMAX
| Q4 25 | 1.2% | 10.4% | ||
| Q3 25 | 5.7% | 1.8% | ||
| Q2 25 | 17.1% | 2.2% | ||
| Q1 25 | 6.1% | 2.3% | ||
| Q4 24 | 33.3% | 9.1% | ||
| Q3 24 | 16.3% | 1.7% | ||
| Q2 24 | 4.5% | 2.4% | ||
| Q1 24 | 0.1% | 3.3% |
现金转化率BCYCRMAX
| Q4 25 | — | 28.39× | ||
| Q3 25 | — | 4.45× | ||
| Q2 25 | — | 0.97× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 10.28× | ||
| Q3 24 | — | 18.22× | ||
| Q2 24 | — | 4.29× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BCYC
暂无分部数据
RMAX
| Franchising Segment | $50.1M | 70% |
| Broker Fees | $13.9M | 20% |
| Annual Dues | $7.4M | 10% |
